Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$40,000.00
Jul 5, 2021
218782
218782
Provide assistance to mitigate impacts of Covid-19
$49,337.00
Jun 1, 2021
For-profit organization
Small molecule drug development for COVID
973631
Using a bioassay guided fractionation method, AffinityImmuno identified a natural product that is a potent inhibitor of SARS-CoV-2 spike protein binding to ACE2. Research on this natural product is to be accelerated and tested in an series of SARS-CoV-2 permissible cell lines and a hamster model of Covid-19 in order to determine whether to pursue a human health product.
$250,000.00
Apr 1, 2020
For-profit organization
Covid 19 diagnostic
947829
A major roadblock in COVID-19 research is the lack of available reagents for research and manufacturing. The need for research reagents is urgent. AffinityImmuno has developed a very rapid turnaround immunization protocol and has the first available antibodies on the market.
AffinityImmuno has raised antibodies against the full extracellular domain of COVID-19 spike protein and nucleocapsid and has the opportunity to develop critical components that will be used in R&D of diagnostic products and products that will affect the disease course. Because the antibodies were raised in chicken we have a large supply and are now working towards developing critical products in partnership with the private sector and academia.
$50,000.00
Sep 4, 2019
214082
214082
Support the development of an antibody discovery platform
$31,200.00
Sep 4, 2019
214082
214082
Support the development of an antibody discovery platform
$35,951.00
Jul 2, 2018
For-profit organization
Novel platform for high affinity recombinant chicken monoclonal antibodies
909745
The goal of this project is to develop a recombinant antibody platform using chickens.